Insmed Incorporated

Insmed Incorporated
Insmed Incorporated

Insmed Incorporated is a global biopharmaceutical company focused on the unmet needs of patients with serious and rare diseases. The company is dedicated to developing and bringing to market novel, transformational therapies that make a real difference to patients. The company’s lead product candidate, ALIS, is currently under FDA review for the treatment of nontuberculous mycobacterial (NTM) lung disease caused by Mycobacterium avium complex (MAC), a rare and often chronic infection that can cause irreversible lung damage and can be fatal. For more information, visit www.insmed.com.

Stories by Insmed Incorporated